Statements (29)
Predicate | Object |
---|---|
gptkbp:instanceOf |
gptkb:chemical_compound
|
gptkbp:approvedBy |
true
|
gptkbp:ATCCode |
gptkb:C07AB03
|
gptkbp:Bioavailability |
50%
|
gptkbp:CASNumber |
gptkb:29122-68-7
|
gptkbp:drugClass |
beta blocker
|
gptkbp:hasInChIKey |
METKIMKYRPQLGS-UHFFFAOYSA-N
|
gptkbp:hasMolecularFormula |
C14H22N2O3
|
gptkbp:hasSMILES |
CC(C)NCC(CO)Oc1ccc(cc1)CC(=O)N
|
https://www.w3.org/2000/01/rdf-schema#label |
ChEMBL1044
|
gptkbp:indication |
myocardial infarction
hypertension angina pectoris |
gptkbp:IUPACName |
4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenylacetamide
|
gptkbp:KEGGID |
gptkb:D00222
|
gptkbp:mechanismOfAction |
beta-1 adrenergic receptor antagonist
|
gptkbp:molecularWeight |
266.34
|
gptkbp:name |
gptkb:Atenolol
|
gptkbp:PubChem_CID |
2162
CHEBI:2269 DB00335 CHEMBL1044 |
gptkbp:routeOfAdministration |
oral
|
gptkbp:synonym |
gptkb:Atenololum
gptkb:Tenormin |
gptkbp:target |
beta-1 adrenergic receptor
|
gptkbp:UNII |
50VV3VW0TI
|
gptkbp:bfsParent |
gptkb:CBD
|
gptkbp:bfsLayer |
5
|